Purpose. Based on the assumption that bronchial asthma has certain neurogenic paroxysmal mechanism, and on the existence a lot of similarities and connections of asthma with other paroxysmal diseases - like breath-holding attacks, epilepsy and migraine, we decided to investigate efficacy of some anticonvulsants in bronchial asthma.
Methods. 10 patients with asthma received topiramate, 10 patients – carbamazepine, and 10 patients – ethosuximide during 3 months. Peak-flow rates and frequency of exacerbations were registered before, during and at the end of the treatment.
Results. Complete and stable remission was achieved in 8 patients of topiramate group and in 7 patients of carbamazepine group during 3-month treatment when all other antiasthmatic therapy was abandoned. In these patients asthmatic attacks completely disappeared, and peak-flow rates increased till normal levels. No significant improvements were registered in 2 patient from topiramate, 3 – from carbamazepine, and 10 – from ethosuximide group.
Conclusions. Based on high efficacy of monotherapy by some anticonvulsants in asthmatic patients, we suppose that it is necessary to continue investigations. In aim to confirm these results it is necessary to perform double-blind randomized placebo-controlled study with various anticonvulsants.